LifeMD, Inc. (NASDAQ:LFMD) Receives $9.14 Consensus PT from Analysts

LifeMD, Inc. (NASDAQ:LFMD) has been assigned an average recommendation of “Moderate Buy” from the nine ratings firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and seven have given a buy recommendation to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $9.1429.

A number of equities analysts have commented on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of LifeMD in a research report on Friday, March 27th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of LifeMD in a research report on Tuesday, March 10th. Zacks Research raised shares of LifeMD from a “strong sell” rating to a “hold” rating in a research report on Friday, December 19th. HC Wainwright lifted their price objective on shares of LifeMD from $9.00 to $10.00 and gave the stock a “buy” rating in a research report on Wednesday, March 11th. Finally, Mizuho raised shares of LifeMD from a “neutral” rating to an “outperform” rating and lifted their price objective for the stock from $6.00 to $8.00 in a research report on Monday, March 16th.

LifeMD Price Performance

LFMD stock opened at $3.83 on Friday. The company has a fifty day moving average price of $3.39 and a two-hundred day moving average price of $4.14. LifeMD has a one year low of $2.56 and a one year high of $15.84. The stock has a market cap of $183.73 million, a price-to-earnings ratio of 14.73 and a beta of 1.77.

LifeMD (NASDAQ:LFMD) last released its quarterly earnings data on Monday, March 9th. The company reported ($0.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.03). LifeMD had a negative return on equity of 83.93% and a net margin of 6.58%.The company had revenue of $46.87 million for the quarter, compared to the consensus estimate of $48.57 million. Research analysts anticipate that LifeMD will post -0.56 EPS for the current fiscal year.

Institutional Investors Weigh In On LifeMD

Institutional investors have recently modified their holdings of the business. Caitong International Asset Management Co. Ltd bought a new stake in shares of LifeMD in the fourth quarter valued at about $36,000. Magnus Financial Group LLC bought a new stake in shares of LifeMD in the fourth quarter valued at about $41,000. Jain Global LLC bought a new stake in shares of LifeMD in the fourth quarter valued at about $45,000. Quarry LP bought a new stake in shares of LifeMD in the third quarter valued at about $52,000. Finally, Tower Research Capital LLC TRC boosted its position in shares of LifeMD by 110.4% in the second quarter. Tower Research Capital LLC TRC now owns 4,674 shares of the company’s stock valued at $64,000 after acquiring an additional 2,452 shares during the period. Institutional investors own 35.52% of the company’s stock.

LifeMD Company Profile

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.